Saint-Prex

Alliance Promotion Microbiote To Welcome Ferring Pharmaceuticals, Pelican Health and Polepharma as New Members

Retrieved on: 
목요일, 11월 9, 2023
Gastroenterology, Science, APM, Urology, Translation, Medication, Maternal health, Research, Ferring Pharmaceuticals, Quality of life, Rehabilitation, Mother, Medicine, Saint-Prex, Microbiota, Reproductive medicine, Patient, Pharmaceutical industry, Medical device, Ferring

With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.

Key Points: 
  • With more than 20 current members, APM today welcomes Ferring Pharmaceuticals, Pelican Health and Polepharma, three major contributors to the development, the production, and the commercialization of microbiome-based therapeutic and diagnostic innovations for patients.
  • Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology.
  • Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth.
  • www.polepharma.com
    Hervé Affagard, President of Alliance Promotion Microbiote states "We are thrilled to extend a warm welcome to Ferring Pharmaceuticals, Pelican Health, and Polepharma as they join our microbiome-focused association.

Soundport, the New Domicile of Ferring Pharmaceuticals A/S is Inaugurated

Retrieved on: 
목요일, 10월 6, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Sustainability, Environment, Health, LinkedIn, Leadership in Energy and Environmental Design, General manager, YouTube, Maternal health, Partner, LEED, Architecture, Reproductive medicine, Mother, Copenhagen Airport, Gastroenterology, Twitter, Instagram, Multimedia, Urology, Gold, Water, Ferring Pharmaceuticals, Medication, Saint-Prex, Fine chemical, Kastrup, Facebook, Sound hole, Ferring

Soundport is Ferring Pharmaceuticals A/S new domicile and is the companys biggest site for biopharmaceutical research & development.

Key Points: 
  • Soundport is Ferring Pharmaceuticals A/S new domicile and is the companys biggest site for biopharmaceutical research & development.
  • Jacobs Engineering were the main technical and engineering advisors until 2019, when Novo Nordisk Engineering took over the execution of the plans.
  • On the plinth the domicile is resting with glazed windows, with a view towards water on all three sides.
  • Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.

Ferring Receives Positive Vote from U.S. FDA Advisory Committee for RBX2660

Retrieved on: 
목요일, 9월 22, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Infectious Diseases, Clinical Trials, Clostridioides difficile infection, Symptoms of COVID-19, Health, Inflammation, Therapy, Ferring Pharmaceuticals, Saint-Prex, Safety, Incidence, Center, Twitter, Risk, MD, FDA, Food, Diarrhea, LinkedIn, CP, FACG, Yale School of Medicine, AGAF, Patient, Regulation of tobacco by the U.S. Food and Drug Administration, Breakthrough therapy, Maternal health, Gastroenterology, Colitis, Pain, CDC, Centers for Disease Control and Prevention, Journal of Managed Care & Specialty Pharmacy, Medication, Diagnosis, Vaccine, Fast Track, Death, Committee, Research, BLA, Nausea, Fever, Reproductive medicine, Multimedia, Clostridium difficile, Urology, CDI, Recurrence, Mother, Pharmaceutical industry, Medical device, Animal, Ferring

The advisory committee provides recommendations to the FDA, which the agency may consider but is not required to follow, when making its decision.

Key Points: 
  • The advisory committee provides recommendations to the FDA, which the agency may consider but is not required to follow, when making its decision.
  • The committees vote is a step toward potentially addressing the debilitating cycle of recurrence and the suffering faced by these patients.
  • The clinical development program for RBX2660 included six studies with a total of 1061 participants, of which 978 were treated with RBX2660.
  • RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA).

Paxos Sees Interest in Digital Assets Growing Faster in Latin America Than Any Other Region

Retrieved on: 
화요일, 9월 13, 2022
Crypto, Mithril, Saint-Prex, Adoption, Founders Fund, Mastercard, Société Générale, Growth, MercadoLibre, Investment, Bank, Innovation, Credit Suisse, Technology, PayPal, Solution, Paxos, Interactive Brokers, Awareness, Bank of America, Internet access, Cryptocurrency, Nubank

NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Today, Paxos, the leading regulated blockchain infrastructure platform, published "What's Driving the Immense Growth of Crypto in Latin America?", a new white paper that delves into the consumer and market trends fueling adoption of digital assets in the region. Following the successful integration of crypto into numerous Latin American fintech apps like Mercado Libre, Nubank, PicPay and others, Paxos sought to understand the drivers behind the region's robust embrace of cryptocurrency. Crypto usage in Latin America has increased by 1370% from 2019-2021, according to Chainalysis.    

Key Points: 
  • NEW YORK, Sept. 13, 2022 /PRNewswire/ -- Today, Paxos , the leading regulated blockchain infrastructure platform, published "What's Driving the Immense Growth of Crypto in Latin America?
  • ", a new white paper that delves into the consumer and market trends fueling adoption of digital assets in the region.
  • Crypto usage in Latin America has increased by 1370% from 2019-2021, according to Chainalysis.
  • With offices in New York, London and Singapore, Paxos takes a global approach to modernizing the financial system.

Lirium to Power Digital Asset Access for Mexican FinTech; Expands Footprint Across Latin America

Retrieved on: 
화요일, 8월 23, 2022
CEO, Lilium, Smartphone, Brubank, Insurance, Awareness, Treasury, AMI, API, C&C 36-1, EUR, Latin Americans, Albite, Compliance, Risk, Grupo Financiero Galicia, GBP, Saint-Prex, Adoption, DAE, Cryptocurrency, Patagon

VADUZ, Liechtenstein, Aug. 23, 2022 /PRNewswire/ -- Lirium, a leading licensed provider of B2B2C digital asset access solutions, will begin powering digital currency access and settlement services for Mexican digital wallet Albit, reaching more than 2 million customers.

Key Points: 
  • VADUZ, Liechtenstein, Aug. 23, 2022 /PRNewswire/ -- Lirium, a leading licensed provider of B2B2C digital asset access solutions, will begin powering digital currency access and settlement services for Mexican digital wallet Albit, reaching more than 2 million customers.
  • Albit is Lirium's first client in Mexico, a country with significant potential for adoption of alternative payment methods and alternative digital asset investment.
  • Lirium first launched its turnkey digital assets access solution directed at traditional financial institutions and fintechs in Argentina one year ago.
  • Latin America has significant smartphone and digital wallet penetration, as well as crypto awareness with considerable latent demand.

Ferring Announces U.S. FDA Advisory Committee Meeting for RBX2660 its Investigational Microbiota-Based Live Biotherapeutic

Retrieved on: 
화요일, 8월 9, 2022
Health, FDA, Research, Pharmaceutical, Science, Biotechnology, FDA, Saint-Prex, Regulation of tobacco by the U.S. Food and Drug Administration, Multimedia, Nausea, Risk, Urology, Colitis, Maternal health, Inflammation, Recurrence, Death, Journal of Managed Care & Specialty Pharmacy, Diagnosis, CDI, YouTube, Center, Breakthrough therapy, Research, Pain, Diarrhea, Clostridioides difficile infection, Fever, CDC, Review, Patient, Reproductive medicine, Twitter, Therapy, Centers for Disease Control and Prevention, Ferring Pharmaceuticals, BLA, Vaccine, Medication, Gastroenterology, Fast Track, LinkedIn, Mother, CP, Food, Health, Clostridium difficile, Symptoms of COVID-19, Pharmaceutical industry, Medical device, Animal, Ferring

The cycle of recurrent CDI represents a significant public health burden, and Ferring is working to address that unmet need.

Key Points: 
  • The cycle of recurrent CDI represents a significant public health burden, and Ferring is working to address that unmet need.
  • The FDA intends to live stream the advisory committee meeting on the agency's YouTube page, and the meeting will also be webcast from the FDA website.
  • RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA).
  • Ferring Pharmaceuticals is a research driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives.

Ferring Announces Ground-Breaking and Inclusive Family Building Benefits Package for All Its Employees Globally

Retrieved on: 
목요일, 7월 14, 2022
Health, Pharmaceutical, Maternal health, Compliance, Infertility, Family, Multimedia, Awareness, European Society of Human Reproduction and Embryology, Environment, ART, Urology, Embryology, Human Reproduction (journal), Patient, Saint-Prex, Reproduction, Love, Gastroenterology, Research, Miscarriage, Executive Committee, Reproductive medicine, Ferring Pharmaceuticals, Investor, Mental health, European Society of Cardiology, Fertility, World Health Organization, Mother, Adoption, Medication, Parent, Birth control, Health insurance, Ferring

As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees.

Key Points: 
  • As part of this commitment, Ferring has announced the introduction of a new global family building benefits package for its employees.
  • View the full release here: https://www.businesswire.com/news/home/20220707005467/en/
    The comprehensive package recognises the complexities of building a family and aims to enable different family building options by removing the financial barriers and providing access to quality care.
  • Building on the long-standing fertility benefits package offered to its US-based employees via its provider, Progyny, Ferring has now engaged Carrot, to support its employees in the rest of the world.
  • The new family building support package ensures a global standard for support irrespective of location, role or family circumstances.

Ferring Announces New Collaboration for Development of Olamkicept

Retrieved on: 
목요일, 6월 9, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Saint-Prex, ECCO, European, Urology, Senior, UC, Olamkicept, Maternal health, Patient, Reproductive medicine, IBD, Gastroenterology, Mother, Ferring Pharmaceuticals, Inflammatory bowel disease, Interleukin 6, Safety, Pharmaceutical industry, Ferring

Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.

Key Points: 
  • Ferring Pharmaceuticals today announced it has entered into a strategic collaboration with I-Mab to further develop olamkicept in inflammatory bowel disease (IBD) and related inflammatory conditions.
  • Ferring had previously entered into a license agreement with I-Mab in 2016 that granted I-Mab exclusive rights to develop and commercialize olamkicept in Greater China and South Korea.
  • This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone.
  • We are excited to expand our collaboration and advance olamkicept globally, as we continue to invest in our specialty area of gastroenterology.